JMP Securities analyst Reni Benjamin reiterated a Buy rating on Spectrum Pharmaceuticals (SPPI – Research Report) today and set a price target of $4.00. The company’s shares closed last Friday at $0.44.
According to TipRanks, Benjamin is an analyst with an average return of -10.3% and a 33.50% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Spectrum Pharmaceuticals, and Allogene Therapeutics.
In addition to JMP Securities, Spectrum Pharmaceuticals also received a Buy from H.C. Wainwright’s Edward White in a report issued on November 11. However, on November 16, B.Riley Financial downgraded Spectrum Pharmaceuticals (NASDAQ: SPPI) to a Hold.
The company has a one-year high of $1.81 and a one-year low of $0.36. Currently, Spectrum Pharmaceuticals has an average volume of 4.58M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It operates through the following brands: FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA. The company was founded in December 1987 and is headquartered in Henderson, NV.
Read More on SPPI: